The historical rank and industry rank for Voyager Therapeutics's Net Margin % or its related term are showing as below:
VYGR'
s Net Margin % Range Over the Past 10 Years
Min: -1158.79 Med: -151.87 Max: 52.93
Current: -319.61
VYGR's Net Margin % is ranked worse than 65.68% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs VYGR: -319.61
Voyager Therapeutics (NAS:VYGR) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Voyager Therapeutics Net Margin % Related Terms
Voyager Therapeutics Net Margin % Historical Data
* Premium members only.
The historical data trend for Voyager Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Voyager Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyager Therapeutics (VYGR) has a Net Margin % of -1,077.40% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Voyager Therapeutics and its competitors. According to the industry distribution chart, Voyager Therapeutics ranks #622 out of 947 companies in the Biotechnology industry, placing it in the top 65.7%.
Is Voyager Therapeutics' Net Margin % too high?
Voyager Therapeutics' current Net Margin % is -1,077.40%. Based on the distribution chart, Voyager Therapeutics ranks #622 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Voyager Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Net Margin % compare to CRBU and OBIO?
According to the Biotechnology industry distribution chart, Voyager Therapeutics ranks #622 out of 947 companies for Net Margin %. This places Voyager Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current Net Margin % is -1,077.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (VYGR) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.69, compared to a current price of $3.68 — trading 117.8% above its estimated fair value. The current Net Margin % is -1,077.40%. Voyager Therapeutics' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Voyager Therapeutics (VYGR), the current Net Margin % is -1,077.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voyager Therapeutics (VYGR) Overvalued in 2026?
Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued.
The current stock price of $3.68 is trading 117.8% above its estimated GF Value™ of $1.69.
GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.
Key valuation signals for VYGR:
Net Margin %: -1,077.40%
GF Value™: $1.69 vs. price of $3.68 (117.8% above fair value)
No single metric tells the full story. See the VYGR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
55GF Score
Get the complete analysis for VYGR
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VYGR has been successfully added to your 
